COL4A3BP Antibody

What is COL4A3BP and why is it important in research?

COL4A3BP (now also referred to as CERT1) encodes a kinase that specifically phosphorylates the N-terminal region of the non-collagenous domain of the alpha 3 chain of type IV collagen, known as the Goodpasture antigen . This protein has dual functions: as a kinase involved in phosphorylation events and as a ceramide transfer protein that mediates intracellular trafficking of ceramides in a non-vesicular manner . It is particularly important in research related to autoimmune conditions (as Goodpasture disease results from an autoimmune response directed at this antigen), lipid metabolism, and cellular signaling pathways .

What are the key isoforms of COL4A3BP and how do they differ?

The COL4A3BP gene is alternatively spliced, producing multiple protein isoforms with different functional properties:

• GPBP (full-length variant) - Contains a serine-rich domain of 26 amino acid residues

• GPBPΔ26 (shorter variant) - Lacks the serine-rich domain encoded by exon 11

These isoforms exhibit different binding capacities to the Goodpasture auto-antigen and different kinase activities. The full-length GPBP shows stronger binding and kinase activity compared to GPBPΔ26 . Both isoforms function as ceramide transfer proteins (CERT), but they are differentially expressed during development and may have distinct biological roles .

What is the cellular localization of COL4A3BP?

COL4A3BP is predominantly located in the cytoplasm, with preferential localization to the Golgi apparatus. It is also found in the endoplasmic reticulum . The protein contains domain structures that facilitate this localization:

• An amino-terminal pleckstrin homology (PH) domain

• A middle FFAT motif (two phenylalanines in acidic tract)

• A carboxyl-terminal START domain

The PH domain permits localization to the Golgi apparatus, while the FFAT domain allows association with the endoplasmic reticulum, enabling the protein to transfer ceramides between these organelles .

What applications are COL4A3BP antibodies most commonly used for?

Based on the available data, COL4A3BP antibodies are validated for the following applications:

The selection of application should be based on the specific research question and experimental system .

How should I optimize immunohistochemistry protocols for COL4A3BP antibodies?

For optimal IHC staining using COL4A3BP antibodies, consider the following methodological recommendations:

• Antigen retrieval: Use TE buffer at pH 9.0 as the primary method; alternatively, citrate buffer at pH 6.0 can be used .

• Dilution range: Begin with 1:50-1:200 dilution for polyclonal antibodies and adjust based on signal strength .

• Verified samples: Human thyroid cancer, human gastric cancer, human pancreas, and human kidney tissues have been successfully used for IHC validation .

• Blocking: Use 5% Milk-TBST for blocking and as antibody diluent for consistent results .

• Incubation: For optimal binding, incubate primary antibody overnight at 4°C .

Always perform antibody titration in your specific testing system to obtain optimal results, as sensitivity may be sample-dependent .

What are the recommended protocols for Western blot using COL4A3BP antibodies?

For Western blot applications with COL4A3BP antibodies:

• Sample preparation: Multiple tissue types have yielded positive results including mouse brain, HEK-293 cells, human pancreas, mouse kidney, and rat brain tissues .

• Dilution range: Use 1:2000-1:10000 for primary antibody incubation .

• Blocking conditions: 5% Milk-TBST is recommended for blocking and as antibody diluent .

• Primary antibody incubation: Incubate overnight at 4°C for optimal results .

• Expected molecular weight: The calculated molecular weight of COL4A3BP is 71 kDa, but the observed molecular weight in Western blots typically ranges from 80-89 kDa, likely due to post-translational modifications .

• Secondary antibody: For rabbit-hosted COL4A3BP antibodies, use anti-rabbit IgG with appropriate conjugation (HRP is common) .

How can I address weak or no signal when using COL4A3BP antibodies?

If experiencing weak or no signal with COL4A3BP antibodies, consider these approaches:

• Antibody dilution: Decrease the dilution factor (use more concentrated antibody) within the recommended range (e.g., start with 1:50 for IHC or 1:2000 for WB) .

• Antigen retrieval: Ensure proper antigen retrieval by testing both recommended methods (TE buffer pH 9.0 and citrate buffer pH 6.0) .

• Incubation time: Extend the primary antibody incubation time to overnight at 4°C .

• Sample preparation: Verify protein expression in your specific sample type; consult the list of verified positive samples (mouse brain, HEK-293 cells, human pancreas tissue, etc.) .

• Storage conditions: Ensure the antibody has been properly stored at -20°C and has not undergone multiple freeze-thaw cycles .

• Verify antibody viability: Use a known positive control sample where COL4A3BP expression has been confirmed .

What factors should I consider when selecting between polyclonal and monoclonal COL4A3BP antibodies?

The choice between polyclonal and monoclonal antibodies should be guided by your specific research needs:

Polyclonal antibodies (like E-AB-14885, 15191-1-AP):

• Recognize multiple epitopes on COL4A3BP, potentially increasing sensitivity

• Useful for detecting low-abundance proteins or denatured proteins

• Show broader species cross-reactivity (often reactive with human, mouse, and rat)

• May have higher background in some applications

Monoclonal antibodies:

• Recognize a single epitope, providing higher specificity

• More consistent lot-to-lot with less background variation

• Potentially lower sensitivity for detecting native proteins

• May have more restricted species reactivity

For COL4A3BP research requiring detection of specific isoforms, consider the immunogen location relative to the alternative splicing region (exon 11). Many available antibodies are raised against recombinant proteins or N-terminal regions (residues 1-50), which may detect both GPBP and GPBPΔ26 isoforms .

How should I address background issues in immunohistochemistry with COL4A3BP antibodies?

High background in IHC can interfere with specific signal detection. To minimize background when using COL4A3BP antibodies:

• Optimize blocking: Use 5% Milk-TBST or add 0.1% BSA to the blocking buffer as done in some validated protocols .

• Antibody dilution: Use the highest dilution that still produces specific signal (e.g., 1:200 for IHC) .

• Washing steps: Increase the number and duration of washes between antibody incubations.

• Secondary antibody optimization: Ensure secondary antibody is properly diluted and has minimal cross-reactivity with the sample species.

• Endogenous peroxidase quenching: For HRP-based detection systems, adequately quench endogenous peroxidase activity.

• Evaluate fixation: Overfixation can increase background; test different fixation protocols if possible.

• Test antibody specificity: Consider validating antibody specificity using knockout or knockdown controls .

How can I distinguish between COL4A3BP isoforms in experimental systems?

Distinguishing between GPBP and GPBPΔ26 isoforms requires specific methodological approaches:

• PCR-based detection:

  • Design primers flanking exon 11 to generate amplicons of different sizes for the two splice variants

  • In zebrafish models, researchers successfully used this approach to identify both isoforms

• Immunoblotting:

  • Both isoforms can be detected on Western blots with different mobility patterns

  • The full-length GPBP shows lower mobility compared to GPBPΔ26

  • The observed weight difference corresponds to the 26-amino acid serine-rich domain

• Specific antibodies:

  • Consider using antibodies raised against the 26-amino acid region present only in the full-length isoform

  • For functional studies, recombinant expression of FLAG-tagged isoforms can be visualized using anti-FLAG antibodies

• Functional assays:

  • Kinase activity assays can differentiate between isoforms, as GPBP shows stronger kinase activity

  • Ceramide transfer assays may also reveal functional differences between the isoforms

What knockout/knockdown approaches are effective for studying COL4A3BP function?

Several effective genetic manipulation strategies have been used to study COL4A3BP function:

• CRISPR-Cas9 knockout:

  • Genome-wide CRISPR knockout screens have included COL4A3BP

  • This approach provides complete protein elimination but may affect all isoforms

• Splice-blocking morpholinos:

  • In zebrafish, specifically designed morpholinos targeting exon 11 (MO gpbp-SA) effectively eliminated the full-length gpbp without affecting gpbpΔ26

  • This allows for isoform-specific functional studies

• 5'UTR-targeting morpholinos:

  • Also used in zebrafish to knockdown all isoforms

  • Enables comparison with isoform-specific knockdown effects

• Rescue experiments:

  • Synthetic mRNA co-injection with morpholinos can confirm specificity

  • Differential rescue with gpbp vs. gpbpΔ26 mRNAs revealed isoform-specific functions in development

The phenotypes associated with COL4A3BP knockdown in zebrafish included increased apoptosis in somites, brain edema, and loss of myelinated tracks, suggesting important roles in normal skeletal muscle and brain development .

How is COL4A3BP involved in disease pathogenesis and what research models are most appropriate?

COL4A3BP has been implicated in several disease contexts:

• Autoimmune diseases:

  • Goodpasture disease involves autoimmune responses against the Goodpasture antigen (α3 chain of type IV collagen) that is phosphorylated by COL4A3BP

  • GPBP is overexpressed in many autoimmune conditions

• Developmental disorders:

  • Mutations in CERT1 (COL4A3BP) are associated with intellectual developmental disorder (autosomal dominant 34)

  • Zebrafish models show that disruption of gpbp leads to developmental abnormalities in the brain and somites

• Pulmonary vascular disease:

  • COL4A3BP has been identified in pathway analyses of pulmonary vascular disease, with significant adjusted P values (0.008843249)

• Cancer research:

  • COL4A3BP antibodies have been validated in cancer tissues including thyroid cancer and gastric cancer

  • The protein is implicated in cancer, cell biology, metabolism, and signal transduction research areas

Appropriate research models include:

• Zebrafish for developmental studies (allows isoform-specific manipulation)

• Cell culture models for ceramide transport and Golgi-ER trafficking studies

• Human tissue samples for expression analysis in disease states

• Mouse models for in vivo functional studies

How should I interpret differences in COL4A3BP expression between normal and disease tissues?

When analyzing COL4A3BP expression differences:

• Consider isoform expression ratios:

  • The ratio between GPBP and GPBPΔ26 may be more informative than total protein levels

  • Developmental stages show differential expression of these isoforms

• Cellular localization changes:

  • Assess changes in subcellular distribution (cytoplasm, Golgi apparatus, ER)

  • Altered localization may indicate functional changes even without expression level differences

• Correlation with ceramide metabolism:

  • Interpret COL4A3BP expression in context with ceramide levels and distribution

  • Disruption of nonvesicular ceramide transport can be detrimental to normal tissue function

• Tissue-specific expression patterns:

  • In disease research, compare expression in relevant tissues (e.g., brain, kidney, thyroid)

  • Validated tissues for antibody studies include thyroid cancer, gastric cancer, pancreas, and kidney

• Correlation with apoptosis markers:

  • Research in zebrafish showed COL4A3BP knockdown linked to increased apoptosis

  • Consider co-staining with apoptosis markers when analyzing diseased tissues

What is the significance of COL4A3BP phosphorylation and how can it be studied?

COL4A3BP phosphorylation has significant functional implications:

• Regulatory mechanisms:

  • The serine-rich motif in CERT undergoes phosphorylation, which down-regulates the ER to Golgi transport of ceramide

  • This represents a key regulatory mechanism for ceramide trafficking

• Methodological approaches for studying phosphorylation:

  • Phospho-specific antibodies (if available)

  • Mass spectrometry to identify phosphorylation sites

  • In vitro kinase assays to assess phosphorylation activity

  • Phosphomimetic and phospho-deficient mutants to study functional consequences

• Functional significance:

  • Phosphorylation of COL4A3BP affects its ceramide transfer activity

  • COL4A3BP itself functions as a kinase that phosphorylates the Goodpasture antigen

  • Understanding this dual role as both kinase and phosphorylation target is critical for comprehensive functional studies

• Disease relevance:

  • Altered phosphorylation states may contribute to pathological conditions

  • In Goodpasture disease, abnormal phosphorylation of collagen IV α3 chain may contribute to autoantigen formation

What are the key experimental considerations when studying COL4A3BP's role in ceramide transport?

When investigating COL4A3BP's function in ceramide transport:

Through careful experimental design addressing these considerations, researchers can effectively investigate COL4A3BP's critical role in ceramide homeostasis and related disease mechanisms.